Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus HEXADROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus HEXADROL.
A-METHAPRED vs HEXADROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Category C
Category C
Corticosteroid
Corticosteroid